Orchestra BioMed’s (OBIO) “Buy” Rating Reiterated at Chardan Capital
Chardan Capital reaffirmed their buy rating on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $20.00 target price on the stock. Other equities analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a […]
Chardan Capital reaffirmed their buy rating on shares of Orchestra BioMed (NASDAQ:OBIO – Free Report) in a research report released on Tuesday morning,Benzinga reports. The brokerage currently has a $20.00 target price on the stock. Other equities analysts also recently issued research reports about the company. HC Wainwright reissued a “buy” rating and set a […]
